Flecainide is one of the more effective drugs for controlling certain heart rhythm problems, but it carries a side-effect profile that ranges from mild annoyances to genuinely life-threatening events. The most common complaints are dizziness and visual disturbances, each affecting roughly a third of users, while the most serious risk is proarrhythmia, meaning the drug can paradoxically trigger or worsen the very heart rhythm disorders it is supposed to treat. That tension between effectiveness and danger is why flecainide prescribing comes with more guardrails than most cardiac medications, and why understanding its side effects matters whether you have just started taking it or have been on it for years.
The Everyday Side Effects Most People Notice First
If you take flecainide, the side effects you are most likely to feel have nothing to do with your heart. An early clinical review found that dizziness affected about 30% of patients and visual disturbances affected about 28%, and the two often showed up together.1PubMed. Extracardiac adverse effects of flecainide The visual symptoms are distinctive: people describe blurred vision, difficulty focusing, or seeing bright spots, especially in response to moving lights or transitioning between light and dark. These tend to be worse shortly after a dose peaks in the bloodstream and ease as the drug level falls.
Other reported symptoms include headache, nausea, shortness of breath, and chest discomfort, each occurring in roughly 6 to 9% of patients in that same review.2PubMed. Extracardiac adverse effects of flecainide Fatigue, tremor, and a general unsteadiness on your feet round out the list that most prescribers warn about. For many people these symptoms are tolerable and settle down over the first few weeks, but for others they remain persistent enough to prompt a dose reduction or a switch to a different drug.
Proarrhythmia and the Study That Changed Everything
The most consequential risk of flecainide is proarrhythmia, and the evidence behind it reshaped how cardiologists use the drug. In the late 1980s, a large trial called the Cardiac Arrhythmia Suppression Trial (CAST) set out to test whether suppressing extra heartbeats after a heart attack would improve survival. The logic seemed sound: patients with frequent premature ventricular contractions after a heart attack had a higher death rate, so eliminating those extra beats with drugs like flecainide should help. It did the opposite.
The flecainide and encainide groups had roughly a 3.6-fold increase in arrhythmic death compared with placebo.3PubMed. The Cardiac Arrhythmia Suppression Trial: background, interim results and implications After about 10 months of follow-up, 43 drug-treated patients had died from arrhythmia compared with 16 on placebo. The excess deaths were not limited to sudden arrhythmic events; nonarrhythmic cardiac deaths, including fatal heart attacks with shock, were also significantly more common in the treatment group.4PubMed. Mortality and morbidity in patients receiving encainide, flecainide, or placebo The trial was stopped early.
Subsequent analysis suggested that flecainide’s proarrhythmic effect was amplified when heart tissue was actively starved of blood. Researchers found that while the treatment and placebo groups had similar rates of ischemic episodes, the drug group had a dramatically higher fatality rate when those episodes occurred.5Heart. Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I In practical terms, this means that flecainide is considered unsafe in people with coronary artery disease, prior heart attacks, or any condition that predisposes to poor blood flow in the heart muscle. That single trial is the reason flecainide is now reserved mainly for people with structurally normal hearts.
When Flecainide Converts One Rhythm Problem Into Another
One of flecainide’s more dangerous cardiac side effects is its ability to convert atrial fibrillation into atrial flutter with 1:1 conduction to the ventricles. In atrial fibrillation, the upper chambers of the heart fire chaotically and the lower chambers are somewhat protected by a natural “gatekeeper” that filters out most of those signals. Flecainide can slow the chaotic atrial activity enough to organize it into flutter, but the now-organized signals may pass through to the ventricles at a dangerously fast rate, sometimes exceeding 200 beats per minute.6BMJ. Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide
Case reports illustrate the severity. In one instance, a 59-year-old man on maintenance flecainide developed 1:1 atrial flutter with rapid conduction, and the emergency cardioversion attempt triggered ventricular fibrillation requiring defibrillation.7PubMed Central. Flecainide-Induced Atrial Flutter With 1:1 Conduction Complicated by Ventricular Fibrillation After Electrical Cardioversion In another, a patient developed 1:1 flutter at a ventricular rate of 192 beats per minute while at rest, shortly after receiving intravenous flecainide.8European Heart Journal – Case Reports. Atrial flutter with flecainide-induced 1:1 conduction at a rate <200 b.p.m. at rest: a case report This is why many prescribers add a rate-controlling agent like a beta-blocker or calcium channel blocker alongside flecainide: the rate controller helps ensure that even if flutter develops, the ventricles will not conduct every beat.
Effects on the Heart’s Pumping Ability
Beyond rhythm disturbances, flecainide weakens the heart’s contractile force. This negative inotropic effect exists even in people with normal hearts, but it becomes clinically significant when heart function is already compromised. A study comparing patients with varying degrees of left ventricular dysfunction found that ejection fraction dropped by about 9% in those with normal hearts, by about 13% in those with mild dysfunction, and by roughly 20% in those with more advanced dysfunction.9PubMed. Comparative haemodynamic effects of intravenous flecainide in patients with and without heart failure and with and without beta-blocker therapy Pulmonary wedge pressure, a marker of fluid backing up into the lungs, rose substantially in all groups but was most pronounced in patients who already had impaired pumping.
This is the second major structural restriction on flecainide use. Just as coronary artery disease disqualifies a patient because of the proarrhythmia risk, heart failure or significant left ventricular dysfunction typically disqualifies someone because the drug can tip an already struggling heart into a worse state. The combination of proarrhythmic potential and negative inotropy is why flecainide’s prescribing guidelines are narrower than those for most antiarrhythmics.
The Pill-in-the-Pocket Approach and Its Safety Record
Many people with infrequent episodes of atrial fibrillation use flecainide on an as-needed basis, taking a single large dose at the onset of symptoms rather than staying on the drug daily. This “pill-in-the-pocket” strategy avoids chronic exposure and its cumulative side effects, but the loading dose carries its own risks. In a study of 273 patients using this approach, significant adverse events occurred in about 3%, including symptomatic low blood pressure, slow heart rates, and 1:1 atrial flutter. All of the serious events in that cohort happened in patients taking 300 mg of flecainide or 600 mg of the related drug propafenone.10PubMed. Safety of Pill-in-the-Pocket Class 1C Antiarrhythmic Drugs for Atrial Fibrillation
A separate study found a higher rate of problems: major adverse events occurred in 6% of patients, nearly all during the very first out-of-hospital dose. Events included syncope, presyncope, and sinus arrest. That study was actually stopped early because of the frequency of problems during unsupervised first doses.11Heart. Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during ‘pill-in-the-pocket’ treatment The practical takeaway is that the first pill-in-the-pocket dose should almost always be taken under medical monitoring. If that initial dose goes smoothly, subsequent self-administered doses appear to carry a much lower risk.
Kidney Problems and Drug Accumulation
Flecainide is primarily processed by the liver, but about 30% of each dose leaves the body unchanged through the kidneys.12PubMed Central. Flecainide toxicity in renal failure When kidney function declines, that route slows down, drug levels climb, and toxicity risk rises. Case reports document patients developing dangerous heart rhythms and hemodynamic collapse after kidney function deteriorated while they were on a previously stable flecainide dose. Renal impairment, drug interactions that inhibit liver metabolism, and advancing age can all slow drug clearance enough to push blood levels above the safe range.
A case study that tracked drug elimination after toxicity developed found a half-life of nearly 57 hours, roughly five times longer than the typical 11-hour half-life listed on the package insert.13PubMed Central. Flecainide Toxicity From Clinical Pharmacology Perspectives That means once toxicity develops, it does not clear quickly. Standard treatment relies on intravenous sodium bicarbonate, which counteracts flecainide’s effects on the heart’s electrical conduction, plus supportive care until the drug is eliminated.14PubMed. A life-threatening flecainide overdose treated with intravenous fat emulsion
Interactions With Pacemakers and Defibrillators
If you have an implanted pacemaker or defibrillator, flecainide introduces a complication that many patients are not warned about. The drug can raise the amount of electrical energy a pacemaker needs to capture the heart, a measurement called the capture threshold. In one report, a woman in her early 80s had elevated capture thresholds at the time of pacemaker implantation while taking flecainide, and her blood level was found to be above the therapeutic range. Once the drug was stopped, the threshold improved rapidly.15PubMed Central. Flecainide causing elevated capture thresholds on pacemaker implantation The same effect can raise defibrillation thresholds, potentially making an implantable defibrillator less effective at terminating a dangerous rhythm when it fires.16HeartRhythm Case Reports. Intermittent failure to capture: What is the mechanism?
For people with devices, this means periodic threshold checks are especially important when flecainide is started, dose-adjusted, or when kidney or liver function changes. Device programming may need to be adjusted to accommodate higher thresholds, and in some cases the drug simply is not compatible with reliable device function.
Psychiatric and Central Nervous System Effects
Most discussion of flecainide’s neurological effects focuses on the dizziness and visual symptoms mentioned earlier, but the drug occasionally produces more dramatic central nervous system reactions. A published case described a patient who developed a severe depressive psychosis with delusions and auditory hallucinations within days of starting flecainide. The psychiatric symptoms did not respond to standard psychoactive medications, but they resolved completely within days of stopping the antiarrhythmic drug.17PubMed. Central nervous system side effects due to anti-arrhythmia therapy. Psychotic depression due to flecainide
Transient behavioral changes have also been noted in children. In a pediatric study, two patients experienced temporary hyperactivity, though the drug was otherwise well-tolerated hemodynamically in younger age groups.18Journal of the American College of Cardiology. Flecainide acetate for resistant arrhythmias in the young: Efficacy and pharmacokinetics These psychiatric effects are rare, but they are worth knowing about because they can be misattributed to a primary psychiatric condition rather than recognized as a drug reaction. If new mood symptoms or unusual behavior coincide with starting flecainide, the drug should be considered a possible cause.
Pediatric Pharmacokinetics
Children metabolize flecainide differently from adults, and the details matter for dosing. Very young infants, under one year of age, eliminate the drug at roughly the same rate as adults, with a half-life of about 11 to 12 hours. Children between ages one and twelve, however, clear the drug faster, with a mean half-life closer to 8 hours.19Journal of the American College of Cardiology. Flecainide acetate for resistant arrhythmias in the young: Efficacy and pharmacokinetics That shorter half-life means children in that age range may need more frequent dosing or higher weight-based doses to maintain effective blood levels, but it also means that doses err toward underdosing rather than accumulation. The visual side effects (blurred vision) seen in adults also appear in children, though significant hemodynamic side effects were not observed in the pediatric series.
Pregnancy, Fetal Treatment, and Breastfeeding
Flecainide occupies an unusual niche in pregnancy: it is one of the drugs used to treat dangerous fetal arrhythmias by giving it to the mother and letting the drug cross the placenta. A case report measured the fetal-to-maternal drug concentration ratio at 0.72, confirming substantial placental transfer.20PubMed Central. Maternal, fetal, neonatal and breastmilk flecainide concentration during maternal therapy and lactation: a case report That ratio is high enough to achieve therapeutic levels in the fetus when the mother’s dose is appropriately managed.
The breastfeeding question is more reassuring. In the same report, flecainide concentrations were actually higher in breastmilk than in maternal plasma at multiple time points, yet the relative infant dose via breastmilk was only about 5.6% of the maternal dose, and neonatal blood levels were undetectable.21PubMed Central. Maternal, fetal, neonatal and breastmilk flecainide concentration during maternal therapy and lactation: a case report This does not make breastfeeding on flecainide risk-free, and data remain limited to case-level evidence, but it suggests that meaningful infant drug exposure through breast milk is unlikely at standard maternal doses.
Uses Beyond Atrial Fibrillation and Their Own Risk Profiles
Flecainide is not only used for atrial fibrillation and flutter. It also treats supraventricular tachycardias and has found a role in two inherited rhythm disorders where its pharmacology happens to address the underlying defect. In Long QT syndrome type 3 (LQT-3), a genetic mutation causes abnormal sodium channel behavior that prolongs the heart’s electrical recovery. Because flecainide blocks sodium channels, low doses can shorten the dangerously prolonged QT interval. A clinical trial in patients with the specific DeltaKPQ mutation showed that flecainide reduced the corrected QT interval by an average of about 27 milliseconds, with only minimal widening of the QRS complex and no major adverse cardiac effects during the study period.22PubMed Central. Safety and efficacy of flecainide in subjects with Long QT-3 syndrome (DeltaKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial
Flecainide is also used in catecholaminergic polymorphic ventricular tachycardia (CPVT), a condition where stress or exercise triggers dangerous rhythms originating from abnormal calcium handling in heart cells. The drug’s mechanism here likely involves its effects on sodium channels and possibly direct action on the calcium release channels within heart muscle cells.23PubMed Central. Multiple targets for flecainide action: implications for cardiac arrhythmogenesis The side-effect concerns in these patients differ from the atrial fibrillation population: structural heart disease may not be present, so the CAST-derived restrictions are less directly relevant, but the negative inotropic and proarrhythmic potential still demands careful monitoring.
Taste Changes and an Unexpected Sensory Effect
A lesser-known side effect involves taste perception. Animal research found that flecainide selectively enhanced aversion to sour tastes without affecting responses to sweet, salty, bitter, or savory flavors. Mice given flecainide showed reduced preference for acidic solutions and heightened taste nerve responses to acid, an effect that persisted through 30 days of daily dosing.24eNeuro. The Antiarrhythmic Drug Flecainide Enhances Aversion to HCl in Mice While this is an animal study and direct translation to humans is uncertain, it aligns with anecdotal reports from flecainide users who describe a metallic or altered taste, particularly with acidic foods and drinks. The mechanism likely involves flecainide’s sodium channel blockade in taste receptor cells, since sour taste perception relies heavily on those channels.
Rare Organ Toxicity
Extremely rare but documented side effects include lung injury. A case report described a 61-year-old woman who developed rapidly progressive breathing difficulty requiring mechanical ventilation while on flecainide therapy. The lung tissue showed a pattern of acute inflammatory and organizing pneumonia, and flecainide was identified as the likely cause after other explanations were excluded.25PubMed Central. Flecainide-induced pneumonitis: a case report Flecainide-induced lung injury has only been reported in a handful of cases in the medical literature, so it is not something most prescribers routinely screen for. But unexplained shortness of breath or respiratory decline in someone taking flecainide should prompt consideration of the drug as a potential contributor, particularly when more common causes have been ruled out.
Hepatic effects have also been reported rarely. In general, clinicians monitor liver function at baseline and periodically thereafter, though routine monitoring practices vary. The drug’s primary metabolism occurs in the liver through the CYP2D6 enzyme pathway, which means that people who are genetically slow metabolizers through this pathway, or who take other medications that compete for the same enzyme, are at higher risk for drug accumulation and toxicity even with normal kidney function.
Overdose and Emergency Management
Flecainide overdose is a medical emergency that can produce widening of the QRS complex on an electrocardiogram, prolongation of other electrical intervals, and life-threatening rhythm disturbances including ventricular tachycardia and ventricular fibrillation.26PubMed. A life-threatening flecainide overdose treated with intravenous fat emulsion Cardiogenic shock can follow, sometimes rapidly. The standard treatment relies on intravenous sodium bicarbonate, which partly reverses flecainide’s sodium channel blockade by increasing the sodium gradient across heart cell membranes, along with magnesium and aggressive fluid resuscitation.
In cases where conventional treatment is insufficient, intravenous fat emulsion has been used as an experimental rescue therapy. The fat acts as a “lipid sink,” sequestering the drug out of the bloodstream and away from heart tissue. Because the drug’s half-life can extend dramatically in overdose or when clearance pathways are impaired, patients may require prolonged monitoring even after initial stabilization. There is no specific antidote for flecainide, and hemodialysis is not effective at removing it because the drug is highly protein-bound and distributed widely into tissues.